ArticleMolecular and clinical oncology2017

Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.

Machiko Kurimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.